ScinoPharm Taiwan, Ltd. (TPE: 1789)

Market Cap	19.49B
Revenue (ttm)	3.43B
Net Income (ttm)	403.00M
Shares Out	790.74M
EPS (ttm)	0.50
PE Ratio	49.31
Forward PE	n/a
Dividend	0.30 (1.24%)
Ex-Dividend Date	Jul 4, 2024

Volume	111,683
Open	24.45
Previous Close	24.20
Day's Range	24.35 - 24.65
52-Week Range	23.20 - 30.50
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2024

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company offers small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It also provides CRAM services, such as chemistry skill, analy...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2023, ScinoPharm Taiwan's revenue was 3.19 billion, a decrease of -2.39% compared to the previous year's 3.26 billion. Earnings were 287.06 million, a decrease of -18.73%.